With Zejula’s third local approval, Zai ready for mainland China launch

China’s approval of Zejula gives Zai Lab its first approval in mainland China and allows the company to start marketing the PARP inhibitor in the largest of the three markets in which it

Read the full 339 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE